Showing 2391-2400 of 3810 results for "".
Stoking the Embers: Re-exploring Topical Coal Products
https://practicaldermatology.com/columns/clinical-focus-1/stoking-the-embers-re-exploring-topical-coal-products/23825/Whose Photos Are They, Anyway?
https://practicaldermatology.com/topics/practice-management/whose-photos-are-they-anyway/23032/An investigation of the complexities of using patient photos.Keratosis Pilaris: A Rough and Bumpy Review
https://practicaldermatology.com/columns/clinical-focus-1/keratosis-pilaris-a-rough-and-bumpy-review/23618/There are promising interventions for this challenging presentation.Look to the EAST: Shared Decision Making in the Era of New Therapies
https://practicaldermatology.com/topics/atopic-dermatitis/look-to-the-east-shared-decision-making-in-the-era-of-new-therapies/23372/Assessing Efficacy, Accessibility, Safety, and Tolerability is the key to a meaningful dialogue with patients.Evolving Perspectives: The Impact of COVID-19 on the Dermatology Market and Consolidation Activity
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-impact-of-covid-19-on-the-dermatology-market-and-consolidation-activity/23347/Experts weigh in on the effect of COVID-19 on Mergers & Acquisitions trends in dermatology.What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis
https://practicaldermatology.com/topics/psoriasis/what-does-efficacy-cost-evidence-for-relative-cost-effectiveness-of-biologic-therapies-for-psoriasis/23128/Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.What to Look for in an Investment Advisor
https://practicaldermatology.com/topics/practice-management/what-to-look-for-in-an-investment-advisor/21018/Avoid choosing the wrong firm.Update: Biomarkers for Guiding Treatment in Early Stage Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-biomarkers-for-guiding-treatment-in-early-stage-melanoma/23260/A look at current tools for risk stratification of melanoma, controversy surrounding SLNB for staging, and novel adjuvant immunotherapies for early stage disease.Recent Developments: What's Next for the Dermatology Pharmaceutical Industry?
https://practicaldermatology.com/columns/recent-developments/whats-next-for-the-dermatology-pharmaceutical-industry/21974/No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?Are We Overlooking Skin Cancer in Ethnic Minorities?
https://practicaldermatology.com/issues/supplements/are-we-overlooking-skin-cancer-in-ethnic-minorities/21718/Skin cancers in Hispanic and African American patients may be detected at more advanced stages, leading to poorer prognoses and long-term outcomes compared to non-Hispanic whites.